Code
MOG-BASX-01BV
Test
Active-Compendium
81206, 81207
81479
Clinical
Oncology,Pathology
<p><b>Bone Marrow Aspirate:</b> 2 mL in EDTA tube.<br>
<b>Peripheral Blood:</b> 5 mL in EDTA tube.<br>
<b>Note:</b> Test is RNA-based. Please select Extract & Hold - RNA if specimen hold service is desired.<br>
<b>Note:</b> Sodium Heparin tubes are acceptable.</p>
<b>Peripheral Blood:</b> 5 mL in EDTA tube.<br>
<b>Note:</b> Test is RNA-based. Please select Extract & Hold - RNA if specimen hold service is desired.<br>
<b>Note:</b> Sodium Heparin tubes are acceptable.</p>
Flag Active
True
Orderable Test Description
<p>This test uses real-time RT-PCR for quantitative detection of t(9;22) BCR-ABL1 fusion transcripts that result in major p210 (e13a2 and/or e14a2) or minor p190 (e1a2) fusion proteins. Analytical sensitivity is 0.002% for p210 and 0.005% for p190, depending on quality and quantity of the isolated RNA and absence of interfering substances. Log reduction score and percent abnormal are reported, and longitudinal data will appear as a NeoTRACK Result on the report.<br><br>
Testing is New York approved for p210 and p190 only.<br><br>
Test Customization: p230 testing may be ordered as a reflex if p210 and p190 are negative, or as a stand-alone test, BCR-ABL1 Non-Standard p230.</p>
Testing is New York approved for p210 and p190 only.<br><br>
Test Customization: p230 testing may be ordered as a reflex if p210 and p190 are negative, or as a stand-alone test, BCR-ABL1 Non-Standard p230.</p>
Orderable Turn Around Time
5 Days
Orderable Biomarkers
NY Approved
True
Orderable Biomarkers JSON
{"Polymerase Chain Reaction (PCR)": {"Fusions": ["BCR-ABL1"]}}
Keywords string
BCR, ABL1, Translocation, BCR ABL1, p210, p190, t(9;22) BCR-ABL1 Standard p210, p190
Title URL
bcr-abl1-standard-p210-p190
Clinical Significance
This assay is intended for use as an aid in the diagnosis and management of BCR-ABL1 (p210) positive and/or BCR-ABL1 (p190) positive chronic myelogenous leukemia (CML), acute lymphoblastic leukemia (ALL) and other leukemic patients with Philadelphia chromosome, including those undergoing kinase inhibitor therapy (e.g. imatinib, nilotinib, dasatinib).
This test may be used to monitor efficacy of therapy or minimal residual disease (MRD) and is not recommended as a sole primary diagnostic test for CML or other acute leukemia. The trend of these results over time is more informative of disease status than an individual result.
Storage and transportation
Use cold pack for transport, making sure cold pack is not in direct contact with specimen. Ship same day as drawn whenever possible. NYS clients please provide date and time of collection. Please select Extract & Hold - RNA if specimen hold service is desired.